Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse.
Testicular germ cell tumours (TGCTs) are the most common cause of cancer in men between the ages of 15 and 40 years, and, overall, the majority of patients should expect to be cured. The European Germ Cell Cancer Consensus Group has provided clear guidelines for the primary treatment of both seminoma and nonseminomatous germ cell tumours. There is, however, no international consensus on how best to follow patients after their initial management. This must promptly and reliably identify relapses without causing further harm. The standardising of follow-up would result in optimising risk-benefit ratios for individual patients, while ensuring economic use of resources. We have identified the seven common scenarios in managing seminomas and nonseminomas of the various stages and discuss the pertinent issues around relapse and follow-up. We review the available literature and present our comprehensive TGCT follow-up guidelines. Our protocols provide a pragmatic, easily accessible user-friendly basis for other centres to use or to adapt to suit their needs. Furthermore, this should enable future trials to address specific issues around follow-up giving meaningful and useful results.
Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK.
N J
NJ
van As
D C
DC
Gilbert
J
J
Money-Kyrle
D
D
Bloomfield
S
S
Beesley
D P
DP
Dearnaley
A
A
Horwich
R A
RA
Huddart
D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D012008:Recurrence; D013736:Testicular Neoplasms / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*